tablets Espiro are shown as addition to standard treatment using β-blockers for the purpose of the reduction of risk of incidence and lethality connected with cardiovascular diseases in stable patients with dysfunction of a left ventricle (fraction of emission of a left ventricle ≤ 40%) and clinical signs of heart failure after recently postponed myocardial infarction.

Structure

Active ingredient: eplerenon.

1 tablet contains 25 mg or 50 mg of an eplerenon.

Excipients: lactose monohydrate, cellulose of a microcrystalline kroskarmelloz of sodium; gipromelloza; sodium lauryl sulfate; magnesium talc Opadry stearate yellow YS-1-12524-A.

Contraindication

• Hypersensitivity to active ingredient or to any of excipients.
• to Patients with potassium level in blood serum> 5 mmol/l at the time of an initiation of treatment.
• to Patients with a renal failure of heavy degree (rated speed of glomerular filtration <30 ml/min. / 1.73 m ² ).
• to Patients with a liver failure of heavy degree (class C on classification Chayld - I Drink).
• to the Patients accepting kaliysberegayushchy diuretics or powerful CYP inhibitors 3A4 (for example, itrakonazol, ketokonazol, ritonavir, nelfinavir, klaritromitsin, telitromitsin and nefazodon).
• Simultaneous use of an eplerenon in a triple combination together with APF inhibitor and blockers of receptors of angiotensin.

Route of administration

For individual selection of a dosage medicament exists in doses of 25 mg and 50 mg. The maximum daily dose makes 50 mg a day.

Eplerenon can be applied both with food, and irrespective of meal.

Feature of use

by

eplerenon to pregnant women with care.

Children

.

Drivers

With care.

Overdose

Is expected that the most probable manifestations of overdose the person will have an arterial hypotension or a hyperpotassemia. Eplerenon it is impossible to bring out of an organism by means of a hemodialysis. It was shown what eplerenon effectively contacts activated carbon. In case of development of arterial hypotension it is necessary to begin the supporting treatment. At development of a hyperpotassemia it is necessary to begin treatment according to standards.

Side effects

Laboratory researches. Often: increase in urea of blood, increase in level of creatinine. Infrequently: decrease in number of receptors of an epidermal growth factor, increase in level of glucose of blood.

Interaction

use of kaliysberegayushchy diuretics or powerful CYP inhibitors 3A4 (for example, itrakonazol, ketokonazol, ritonavir, nelfinavir, klaritromitsin, telitromitsin and nefazodon).

Contraindicated simultaneous use of an eplerenon in a triple combination together with APF inhibitor and blockers of receptors of angiotensin.

to Store

out of children's reach. To store at a temperature not above 25ºС. Special storage conditions are not required.

Expiration date - 4 years.